Skip to content

Telemedicine and Humidification for Cpap IN Osas Key Treatment (THINK Study)

Effects of Telemedicine and Humidification for Continous Positive Airway Pressure (CPAP) in OSAS.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04300166
Acronym
THINK
Enrollment
100
Registered
2020-03-09
Start date
2020-06-01
Completion date
2022-06-01
Last updated
2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypersomnia, OSA, Sleep, Sleep Apnea, Obstructive, Sleep Disorder

Keywords

Telemedicine, CPAP

Brief summary

The goal of the study is to test the role of telemedicine combined with humidification to check CPAP treatment during the first month to improve adherence and reduce unsolved side effects of therapy.

Detailed description

The primary goal of OSAS therapy is to obtain CPAP adaptation for the highest amount of OSAS patients to reduce the proportion of untreated OSAS in the population. This object is important considering that a longer duration of CPAP treatment is linked with better daytime functioning and metabolic and blood pressure effects of CPAP. The main endpoints will be CPAP usage (defined as the proportion of night with CPAP usage ≥1h); CPAP adherence (defined as the proportion of night with CPAP usage ≥4h); the average nightly usage of CPAP (hour/night); CPAP efficacy (defined as AHI and ESS score). Each measure will be performed after 1 week, 1 month and 6 months.

Interventions

DEVICETelemedicine & Humidification

Wireless control of CPAP usage, adherence, leakage and humidifier usage

Sponsors

Sleep Apnoea Italian Patient Association
CollaboratorUNKNOWN
Andrea Romigi
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Consecutive symptomatic OSAS patients with an AHI and an oxygen desaturation index (ODI) of \>15/h in polysomnography (PSG) or Home Sleep Test (HST) consenting to start long term CPAP treatment.

Exclusion criteria

* Age \<18 years * Unable to communicate in Italian * Previous usage of CPAP treatment * Alcohol consumption \> 4 units \>4 times a week * Acute manifestation of psychiatric diseases * Life expectancy of \< 6 months for any reason * Surgical obesity treatment planned within the next 6 months * Predominantly Central sleep apnea and cheyne stokes respiration

Design outcomes

Primary

MeasureTime frameDescription
CPAP usage1 weekdefined as the proportion of night with CPAP usage ≥1h
CPAP adherence1 weekdefined as the proportion of night with CPAP usage ≥4h

Secondary

MeasureTime frameDescription
average nightly usage of CPAP1 week(hour/night)

Other

MeasureTime frameDescription
Daytime somnolence6 monthsEpworth Sleepiness Scale (ESS) Score
Mask leakage6 monthsL/min
Overall Nocturnal Sleep quality6 monthsPittsburgh Sleep Quality Index (PSQI)
Adverse effects on CPAP6 monthsList of adverse effects
CPAP efficacy: Apnea Hypopnea Index (AHI)6 monthsdefined as Apnea Hypopnea Index (AHI)

Contacts

Primary ContactAndrea Romigi, PhD
andrea.romigi@neuromed.it+390865929636

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026